Small cell carcinoma of the prostate

Rosa Nadal, Michael Schweizer, Oleksandr Kryvenko, Jonathan I. Epstein, Mario A. Eisenberger

Research output: Contribution to journalArticle

74 Citations (Scopus)

Abstract

Pure small-cell carcinoma (SCC) of the prostate is a rare entity and one of the most aggressive malignancies of the prostate. Histologically, prostatic SCCs of the prostate are part of a spectrum of anaplastic tumours of the prostate and are similar to SCCs of the lungs. In most cases, SCC of the prostate is associated with conventional prostatic adenocarcinoma. Both components of these mixed tumours frequently share molecular alterations such as ERG gene rearrangements or AURKA and MYCN amplifications, suggesting a common clonal origin. The clinical behaviour of small-cell prostate carcinomas is characterized by extensive local disease, visceral disease, and low PSA levels despite large metastatic burden. Commonly, the emergence of the SCC occurs in patients with high-grade adenocarcinoma who are often treated with androgen deprivation treatment (ADT). However, SCCs do not usually benefit from ADT. A biopsy of accessible lesions is strongly recommended to identify those with SCC pathological features, as management is undoubtedly affected by this finding. Chemotherapy is the standard approach for treating patients with either localized or advanced prostatic SCC. Despite the emergence of more-aggressive treatment modalities, the prognosis of men with prostatic SCC remains dismal.

Original languageEnglish (US)
Pages (from-to)213-219
Number of pages7
JournalNature Reviews Urology
Volume11
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Small Cell Carcinoma
Prostate
Androgens
Adenocarcinoma
Aurora Kinase A
Neoplasms
Gene Rearrangement
Therapeutics
Biopsy
Drug Therapy
Lung

ASJC Scopus subject areas

  • Urology

Cite this

Nadal, R., Schweizer, M., Kryvenko, O., Epstein, J. I., & Eisenberger, M. A. (2014). Small cell carcinoma of the prostate. Nature Reviews Urology, 11(4), 213-219. https://doi.org/10.1038/nrurol.2014.21

Small cell carcinoma of the prostate. / Nadal, Rosa; Schweizer, Michael; Kryvenko, Oleksandr; Epstein, Jonathan I.; Eisenberger, Mario A.

In: Nature Reviews Urology, Vol. 11, No. 4, 2014, p. 213-219.

Research output: Contribution to journalArticle

Nadal, R, Schweizer, M, Kryvenko, O, Epstein, JI & Eisenberger, MA 2014, 'Small cell carcinoma of the prostate', Nature Reviews Urology, vol. 11, no. 4, pp. 213-219. https://doi.org/10.1038/nrurol.2014.21
Nadal R, Schweizer M, Kryvenko O, Epstein JI, Eisenberger MA. Small cell carcinoma of the prostate. Nature Reviews Urology. 2014;11(4):213-219. https://doi.org/10.1038/nrurol.2014.21
Nadal, Rosa ; Schweizer, Michael ; Kryvenko, Oleksandr ; Epstein, Jonathan I. ; Eisenberger, Mario A. / Small cell carcinoma of the prostate. In: Nature Reviews Urology. 2014 ; Vol. 11, No. 4. pp. 213-219.
@article{c2b00cd84aae475eadab9d07dbbf7b19,
title = "Small cell carcinoma of the prostate",
abstract = "Pure small-cell carcinoma (SCC) of the prostate is a rare entity and one of the most aggressive malignancies of the prostate. Histologically, prostatic SCCs of the prostate are part of a spectrum of anaplastic tumours of the prostate and are similar to SCCs of the lungs. In most cases, SCC of the prostate is associated with conventional prostatic adenocarcinoma. Both components of these mixed tumours frequently share molecular alterations such as ERG gene rearrangements or AURKA and MYCN amplifications, suggesting a common clonal origin. The clinical behaviour of small-cell prostate carcinomas is characterized by extensive local disease, visceral disease, and low PSA levels despite large metastatic burden. Commonly, the emergence of the SCC occurs in patients with high-grade adenocarcinoma who are often treated with androgen deprivation treatment (ADT). However, SCCs do not usually benefit from ADT. A biopsy of accessible lesions is strongly recommended to identify those with SCC pathological features, as management is undoubtedly affected by this finding. Chemotherapy is the standard approach for treating patients with either localized or advanced prostatic SCC. Despite the emergence of more-aggressive treatment modalities, the prognosis of men with prostatic SCC remains dismal.",
author = "Rosa Nadal and Michael Schweizer and Oleksandr Kryvenko and Epstein, {Jonathan I.} and Eisenberger, {Mario A.}",
year = "2014",
doi = "10.1038/nrurol.2014.21",
language = "English (US)",
volume = "11",
pages = "213--219",
journal = "Nature Reviews Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Small cell carcinoma of the prostate

AU - Nadal, Rosa

AU - Schweizer, Michael

AU - Kryvenko, Oleksandr

AU - Epstein, Jonathan I.

AU - Eisenberger, Mario A.

PY - 2014

Y1 - 2014

N2 - Pure small-cell carcinoma (SCC) of the prostate is a rare entity and one of the most aggressive malignancies of the prostate. Histologically, prostatic SCCs of the prostate are part of a spectrum of anaplastic tumours of the prostate and are similar to SCCs of the lungs. In most cases, SCC of the prostate is associated with conventional prostatic adenocarcinoma. Both components of these mixed tumours frequently share molecular alterations such as ERG gene rearrangements or AURKA and MYCN amplifications, suggesting a common clonal origin. The clinical behaviour of small-cell prostate carcinomas is characterized by extensive local disease, visceral disease, and low PSA levels despite large metastatic burden. Commonly, the emergence of the SCC occurs in patients with high-grade adenocarcinoma who are often treated with androgen deprivation treatment (ADT). However, SCCs do not usually benefit from ADT. A biopsy of accessible lesions is strongly recommended to identify those with SCC pathological features, as management is undoubtedly affected by this finding. Chemotherapy is the standard approach for treating patients with either localized or advanced prostatic SCC. Despite the emergence of more-aggressive treatment modalities, the prognosis of men with prostatic SCC remains dismal.

AB - Pure small-cell carcinoma (SCC) of the prostate is a rare entity and one of the most aggressive malignancies of the prostate. Histologically, prostatic SCCs of the prostate are part of a spectrum of anaplastic tumours of the prostate and are similar to SCCs of the lungs. In most cases, SCC of the prostate is associated with conventional prostatic adenocarcinoma. Both components of these mixed tumours frequently share molecular alterations such as ERG gene rearrangements or AURKA and MYCN amplifications, suggesting a common clonal origin. The clinical behaviour of small-cell prostate carcinomas is characterized by extensive local disease, visceral disease, and low PSA levels despite large metastatic burden. Commonly, the emergence of the SCC occurs in patients with high-grade adenocarcinoma who are often treated with androgen deprivation treatment (ADT). However, SCCs do not usually benefit from ADT. A biopsy of accessible lesions is strongly recommended to identify those with SCC pathological features, as management is undoubtedly affected by this finding. Chemotherapy is the standard approach for treating patients with either localized or advanced prostatic SCC. Despite the emergence of more-aggressive treatment modalities, the prognosis of men with prostatic SCC remains dismal.

UR - http://www.scopus.com/inward/record.url?scp=84901192115&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901192115&partnerID=8YFLogxK

U2 - 10.1038/nrurol.2014.21

DO - 10.1038/nrurol.2014.21

M3 - Article

C2 - 24535589

AN - SCOPUS:84901192115

VL - 11

SP - 213

EP - 219

JO - Nature Reviews Urology

JF - Nature Reviews Urology

SN - 1759-4812

IS - 4

ER -